Davies M, et al. – Including strategies and tools for the prompt identification, evaluation, and optimal management of immune–mediated adverse events (imAEs), this study sought to provide education on the current knowledge regarding these events associated with immune checkpoint inhibitor (ICPI) treatment. Data demonstrated a critical role of nurses played in identifying imAEs, educating patients about the importance of timely reporting of potentially relevant symptoms, and assisting in the treatment and follow–up of patients who develop imAEs while on ICPI therapy, as a primary point of contact for patients undergoing oncology treatment.